- Global Pharma News & Resources

Sumitomo Dainippon Pharma and Angelini Announce Partnership for Commercialization of Latuda® (Lurasidone Hydrochloride) in Europe

Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; President: Masayo Tada; hereinafter "Sumitomo Dainippon Pharma") and Angelini S.p.A. (Head Office: Rome, Italy; CEO: Gianluigi Frozzi; hereinafter "Angelini") announced today that the companies have formed a partnership (entering into a license and distribution agreement) with the goal to expand availability in Europe of Latuda® (generic name: lurasidone hydrochloride; hereinafter "LATUDA"), an atypical antipsychotic which was created by Sumitomo Dainippon Pharma.

Under the terms of the agreement, Sunovion Pharmaceuticals Europe Ltd., a subsidiary company of Sumitomo Dainippon Pharma Group, (hereinafter "Sunovion Europe") has granted Angelini exclusive commercialization rights for LATUDA in 29 European countries[*] and in Turkey (hereinafter "Territory"). Sunovion Europe is transferring the marketing authorization for LATUDA in Europe to Angelini. Furthermore, Sumitomo Dainippon Pharma will supply LATUDA bulk tablets, or final products to Angelini.

Angelini will hold the marketing authorization for LATUDA in Europe and will commercialize it in the Territory. Angelini will begin to distribute LATUDA in Italy to mark the first country in the Territory, by the end of 2017. Sunovion Europe will continue to distribute LATUDA in the United Kingdom, Switzerland, Norway, Finland, Sweden, Denmark and the Netherlands, where it has already been launched.

"Sumitomo Dainippon Pharma has been seeking to establish a partnership for commercialization of LATUDA in Europe after a partnership on LATUDA business in Europe with Takeda Pharmaceutical Company Limited was terminated in 2015. We are pleased to announce the partnership with Angelini," said Masayo Tada, Representative Director, President and CEO of Sumitomo Dainippon Pharma. "We expect to provide this therapeutic option to a greater number of patients in Europe."

"Central nervous system (CNS) diseases and disorders are one of our focus therapeutic areas, and we are pleased to enhance our already strong product portfolio by introducing LATUDA," said Gianluigi Frozzi, CEO of Angelini. "We will work closely with Sunovion Europe to make LATUDA available in a greater number of European countries."

* Italy, San Marino, Vatican City, Spain, Andorra, Austria, Bulgaria, Croatia, Cyprus, Czechia, Greece, Hungary, Poland, Portugal, Romania, Slovenia, Slovakia, Russia, Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Ukraine, Tajikistan, Turkmenistan, Uzbekistan